{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:19:34Z","timestamp":1790014774211,"version":"4.0.1"},"reference-count":31,"publisher":"Baishideng Publishing Group Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nephrol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Proliferative lupus nephritis (PLN) is the most severe form of lupus nephritis (LN). There are limited data available on renal outcomes of PLN from developing countries.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To determine the clinicopathological characteristics and long-term outcomes in terms of remission, requirement of kidney replacement therapy (KRT), and patient survival.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>A retrospective analysis was conducted on biopsy-proven focal or diffuse PLN cases diagnosed between 1998 and 2019 at the Sindh Institute of Urology and Transplantation and followed up at the renal clinic for a minimum of 5 years. All patients were induced with a combination of intravenous cyclophosphamide and corticosteroids for 6 months, followed by maintenance treatment with azathioprine (AZA) or mycophenolate mofetil (MMF). Data were analyzed using Statistical Package for the Social Sciences, version 22.0. P  \u2264 0.05 was considered statistically significant.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>The mean age at the onset of systemic lupus erythematosus was 24.12 years \u00b1 8.89 years, and at LN onset, 26.63 years \u00b1 8.61 years. There was a female predominance of 184 (88.9%) cases. Among baseline characteristics, reduced estimated glomerular filtration rate, presence of hypertension, requirement of KRT, and underlying renal histology (International Society of Nephrology\/Renal Pathology Society class IV than class III) were significantly associated with end-stage kidney disease (ESKD) and mortality. The renal outcomes were negatively correlated with age, duration of symptoms, and 24-hour urinary protein excretion. The overall remission rate was 89.8% at the end of induction therapy. At 5 years, 141 (68.11%) patients were in complete and partial remission (94 [45.4%] and 47 [22.7%], respectively). In total, 19 (9.2%) patients required KRT on presentation, and at 5 years, 38 (18.4%) patients developed ESKD, and 28 (13.5%) patients died. Thirty-four (16.4%) patients had a renal relapse, more with AZA than MMF (30 [88.2%] vs  4 [11.76%], respectively; P  = 0.04). Renal survival at 6 months was 89.8%, while at 5 years, it was 68.11%, showing a significant improvement in patients who did not need KRT at the time of presentation (P  &lt; 0.0001).<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Baseline renal functions, requirement of KRT, and diffuse proliferative disease were the most relevant prognostic factors for kidney survival among this cohort. Short-term renal outcomes were good. Long-term outcomes were poorer with AZA-based maintenance therapy than with MMF, with more ESKD and mortality.<\/jats:p>","DOI":"10.5527\/wjn.v14.i2.102713","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T10:24:53Z","timestamp":1744107893000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathological characteristics and long-term outcomes of adult patients with proliferative lupus nephritis"],"prefix":"10.5527","volume":"14","author":[{"given":"Saima","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabassum","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Mubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131482"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314567753"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21049-y"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00009-6"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00443.x"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.10.018"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm245"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.06.006"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs073"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/ar3378"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/srep21132"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004080686"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320926256"},{"key":"B17","doi-asserted-by":"crossref","unstructured":"Rasheed IJ, Mousa BA, Makki HMA. Short-term outcome of proliferative lupus nephritis: a single center study. IJMPS 2017; 19-30","DOI":"10.24247\/ijmpsdec20173"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1576-1"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315595130"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.39026"},{"key":"B21","unstructured":"Radhakrishnan J, Kunis CL, D'Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 147-154"},{"key":"B22","unstructured":"Rabbani MA, Tahir MH, Siddiqui BK, Ahmad B, Shamim A, Shah SM, Ahmad A. Renal involvement in systemic lupus erythematosus in Pakistan. J Pak Med Assoc 2005; 328-332"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309103410"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603063141004"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56317-6"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21597"},{"key":"B28","doi-asserted-by":"crossref","unstructured":"George J, Sankaramangalam KP, Sinha A, Hari P, Dinda AK, Bagga A. Lupus Nephritis in Indian Children: Flares and Refractory Illness. Indian Pediatr 2018; 478-481","DOI":"10.1007\/s13312-018-1337-x"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131995"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014460"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920"}],"container-title":["World Journal of Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-6124\/full\/v14\/i2\/102713.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2220-6124\/full\/v14\/i2\/102713.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T10:25:24Z","timestamp":1744107924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-6124\/full\/v14\/i2\/102713.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":31,"journal-issue":{"issue":"2"},"alternative-id":["102713"],"URL":"https:\/\/doi.org\/10.5527\/wjn.v14.i2.102713","relation":{},"ISSN":["2220-6124"],"issn-type":[{"value":"2220-6124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}